[Doripenem: need for a new carbapenem]

Details

Serval ID
serval:BIB_BE16AB9FFE43
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
[Doripenem: need for a new carbapenem]
Journal
Med Mal Infect
Author(s)
Guery B. P.
ISSN
1769-6690 (Electronic)
ISSN-L
0399-077X
Publication state
Published
Issued date
12/2009
Volume
39
Number
12
Pages
871-6
Language
french
Notes
Guery, B-P
fre
Review
France
Med Mal Infect. 2009 Dec;39(12):871-6. doi: 10.1016/j.medmal.2009.08.014. Epub 2009 Oct 28.
Abstract
Doripenem is a new member of the carbapenem family. Its spectrum is a little wider than meropenem and it is active on some Pseudomonas aeruginosa strains resistant to other carbapenems and on Burkholderia cepacia. Doripenem was evaluated in nosocomial pneumonia including ventilator-acquired pneumonia, complicated intra-abdominal infection, and complicated urinary tract infection. In nosocomial pneumonia, doripenem showed an interesting activity in P. aeruginosa infected patients. This data, along with the global increase in multiresistance, may be an opportunity to optimize our therapeutic options with a new molecule.
Keywords
Animals, *Anti-Bacterial Agents/adverse, effects/chemistry/economics/pharmacology/therapeutic use, Bacterial Infections/drug therapy, Burkholderia cepacia/drug effects, *Carbapenems/adverse effects/chemistry/economics/pharmacology/therapeutic use, Clinical Trials as Topic, Cross Infection/drug therapy, Doripenem, Drug Evaluation, Preclinical, Drug Resistance, Multiple, Bacterial, Humans, Nervous System Diseases/chemically induced, Peritonitis/drug therapy, Pneumonia, Bacterial/drug therapy, Pseudomonas aeruginosa/drug effects, Urinary Tract Infections/drug therapy
Pubmed
Create date
29/04/2021 10:59
Last modification date
30/04/2021 6:38
Usage data